🔗 Share this article

Given that the United States proceeds with historic adjustments to its immunization recommendations, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning coronavirus shots throughout the pandemic and has zeroed in on alleged deaths following Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Public health authorities had intended to announce sweeping changes to the pediatric vaccination calendar recently, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of step with much of the world with insufficient data for improved outcomes. This reveal has been pushed back until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to run the division this calendar year.

Consolidating Power at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain pediatric shot schedules in the US so as to align more similar to Denmark, a country with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial comments, she has kept her attention on immunizations – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, approval processes or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in industry regulation.”

Previous directors of CBER would “understand legal statutes and the research of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who headed the center have had.”

CDER has an immense workload at the agency, the former commissioner stated.

“Many people just focuses on the new drug program, but the generic program authorizes thousands of generic drugs. There’s a biosimilars division, OTC medication office and so forth, and all of those need to be managed,” she explained. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant leadership element to the position, which manages in excess of 5,000 staff members. “It is a enormous management job, if you do it right,” Woodcock said.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a spokesperson said that the “questions stem from incorrect assumptions”.

“This background is consistent with the duties of her position,” the official explained, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial rapid therapy clearance system that reportedly troubled her predecessors. “By what process are these drugs being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, except for shots.”

Established History on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, track record, some experts observe. She published a study using unconfirmed public submissions to assess the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership included revising regulations for recently developed shots and ending “non-essential” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of barring teenage boys from getting COVID-19 vaccines.

“She’s an complete true believer who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a extremely misleading, fraudulent fashion,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|